Výsledky vyhľadávania | Slovenská lekárska knižnica

1.certolizumab pegol

	Stromová štruktúra MeSH - certolizumab pegol `[d05.750.741.125]` látky makromolekulárne [d05] + polyméry [d05.750] + polyetylénglykoly [d05.750.741] + certolizumab pegol `[d05.750.741.125]` cetomakrogol [d05.750.741.250] hydrogél, polyetylénglykol dimetakrylát [d05.750.741.485] nonoxynol [d05.750.741.575] oktoxynol [d05.750.741.610] polidokanol [d05.750.741.630] poloxalén [d05.750.741.650] poloxamér [d05.750.741.667] polyhydroxyetylmetakrylát [d05.750.741.685] polysorbáty [d05.750.741.700]
	`[d12.644.541.500.650.250]` aminokyseliny, peptidy a proteíny [d12] + peptidy [d12.644] + fragmenty peptidové [d12.644.541] + fragmenty imunoglobulínov [d12.644.541.500] + Fab fragmenty imunoglobulínov [d12.644.541.500.650] + abciximab [d12.644.541.500.650.125] certolizumab pegol `[d12.644.541.500.650.250]` oblasť imunoglobulínov, variabilná [d12.644.541.500.650.500] + tuftsín [d12.644.541.500.650.750]
	`[d12.776.124.486.485.114.224.060.500]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + imunoproteíny [d12.776.124.486] + imunoglobulíny [d12.776.124.486.485] + protilátky [d12.776.124.486.485.114] + protilátky monoklonálne [d12.776.124.486.485.114.224] + protilátky monoklonálne humanizované [d12.776.124.486.485.114.224.060] + abciximab [d12.776.124.486.485.114.224.060.125] adalimumab [d12.776.124.486.485.114.224.060.250] alemtuzumab [d12.776.124.486.485.114.224.060.313] baziliximab [d12.776.124.486.485.114.224.060.344] bevacizumab [d12.776.124.486.485.114.224.060.375] brentuximab vedotin [d12.776.124.486.485.114.224.060.438] certolizumab pegol `[d12.776.124.486.485.114.224.060.500]` cetuximab [d12.776.124.486.485.114.224.060.750] daklizumab [d12.776.124.486.485.114.224.060.766] denosumab [d12.776.124.486.485.114.224.060.782] gemtuzumab [d12.776.124.486.485.114.224.060.790] inotuzumab ozogamicín [d12.776.124.486.485.114.224.060.794] ipilimumab [d12.776.124.486.485.114.224.060.798] natalizumab [d12.776.124.486.485.114.224.060.813] nivolumab [d12.776.124.486.485.114.224.060.829] omalizumab [d12.776.124.486.485.114.224.060.844] palivizumab [d12.776.124.486.485.114.224.060.860] panitumumab [d12.776.124.486.485.114.224.060.864] ramucirumab [d12.776.124.486.485.114.224.060.866] ranibizumab [d12.776.124.486.485.114.224.060.868] trastuzumab [d12.776.124.486.485.114.224.060.875] + ustekinumab [d12.776.124.486.485.114.224.060.937]
	`[d12.776.124.486.485.680.650.250]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + imunoproteíny [d12.776.124.486] + imunoglobulíny [d12.776.124.486.485] + fragmenty imunoglobulínov [d12.776.124.486.485.680] + Fab fragmenty imunoglobulínov [d12.776.124.486.485.680.650] + abciximab [d12.776.124.486.485.680.650.125] certolizumab pegol `[d12.776.124.486.485.680.650.250]` oblasť imunoglobulínov, variabilná [d12.776.124.486.485.680.650.500] + tuftsín [d12.776.124.486.485.680.650.750]
	`[d12.776.124.790.651.114.224.060.500]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + globulíny sérové [d12.776.124.790] + imunoglobulíny [d12.776.124.790.651] + protilátky [d12.776.124.790.651.114] + protilátky monoklonálne [d12.776.124.790.651.114.224] + protilátky monoklonálne humanizované [d12.776.124.790.651.114.224.060] + abciximab [d12.776.124.790.651.114.224.060.125] adalimumab [d12.776.124.790.651.114.224.060.250] alemtuzumab [d12.776.124.790.651.114.224.060.375] baziliximab [d12.776.124.790.651.114.224.060.407] bevacizumab [d12.776.124.790.651.114.224.060.438] brentuximab vedotin [d12.776.124.790.651.114.224.060.469] certolizumab pegol `[d12.776.124.790.651.114.224.060.500]` cetuximab [d12.776.124.790.651.114.224.060.750] daklizumab [d12.776.124.790.651.114.224.060.766] denosumab [d12.776.124.790.651.114.224.060.782] gemtuzumab [d12.776.124.790.651.114.224.060.790] inotuzumab ozogamicín [d12.776.124.790.651.114.224.060.794] ipilimumab [d12.776.124.790.651.114.224.060.798] natalizumab [d12.776.124.790.651.114.224.060.813] nivolumab [d12.776.124.790.651.114.224.060.829] omalizumab [d12.776.124.790.651.114.224.060.844] palivizumab [d12.776.124.790.651.114.224.060.860] panitumumab [d12.776.124.790.651.114.224.060.864] ramucirumab [d12.776.124.790.651.114.224.060.866] ranibizumab [d12.776.124.790.651.114.224.060.868] trastuzumab [d12.776.124.790.651.114.224.060.875] + ustekinumab [d12.776.124.790.651.114.224.060.937]
	`[d12.776.124.790.651.680.650.250]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + globulíny sérové [d12.776.124.790] + imunoglobulíny [d12.776.124.790.651] + fragmenty imunoglobulínov [d12.776.124.790.651.680] + Fab fragmenty imunoglobulínov [d12.776.124.790.651.680.650] + abciximab [d12.776.124.790.651.680.650.125] certolizumab pegol `[d12.776.124.790.651.680.650.250]` oblasť imunoglobulínov, variabilná [d12.776.124.790.651.680.650.500] + tuftsín [d12.776.124.790.651.680.650.750]
	`[d12.776.377.715.548.114.224.200.500]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + globulíny [d12.776.377] + globulíny sérové [d12.776.377.715] + imunoglobulíny [d12.776.377.715.548] + protilátky [d12.776.377.715.548.114] + protilátky monoklonálne [d12.776.377.715.548.114.224] + protilátky monoklonálne humanizované [d12.776.377.715.548.114.224.200] + abciximab [d12.776.377.715.548.114.224.200.125] adalimumab [d12.776.377.715.548.114.224.200.250] alemtuzumab [d12.776.377.715.548.114.224.200.375] baziliximab [d12.776.377.715.548.114.224.200.407] bevacizumab [d12.776.377.715.548.114.224.200.438] brentuximab vedotin [d12.776.377.715.548.114.224.200.469] certolizumab pegol `[d12.776.377.715.548.114.224.200.500]` cetuximab [d12.776.377.715.548.114.224.200.750] daklizumab [d12.776.377.715.548.114.224.200.766] denosumab [d12.776.377.715.548.114.224.200.782] gemtuzumab [d12.776.377.715.548.114.224.200.790] inotuzumab ozogamicín [d12.776.377.715.548.114.224.200.794] ipilimumab [d12.776.377.715.548.114.224.200.798] natalizumab [d12.776.377.715.548.114.224.200.813] nivolumab [d12.776.377.715.548.114.224.200.829] omalizumab [d12.776.377.715.548.114.224.200.844] palivizumab [d12.776.377.715.548.114.224.200.860] panitumumab [d12.776.377.715.548.114.224.200.864] ramucirumab [d12.776.377.715.548.114.224.200.866] ranibizumab [d12.776.377.715.548.114.224.200.868] trastuzumab [d12.776.377.715.548.114.224.200.875] + ustekinumab [d12.776.377.715.548.114.224.200.937]
	`[d12.776.377.715.548.680.650.250]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + globulíny [d12.776.377] + globulíny sérové [d12.776.377.715] + imunoglobulíny [d12.776.377.715.548] + fragmenty imunoglobulínov [d12.776.377.715.548.680] + Fab fragmenty imunoglobulínov [d12.776.377.715.548.680.650] + abciximab [d12.776.377.715.548.680.650.125] certolizumab pegol `[d12.776.377.715.548.680.650.250]` oblasť imunoglobulínov, variabilná [d12.776.377.715.548.680.650.500] + tuftsín [d12.776.377.715.548.680.650.750]

predmetové heslo

2.adalimumab

	Stromová štruktúra MeSH - adalimumab `[d12.776.124.486.485.114.224.060.250]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + imunoproteíny [d12.776.124.486] + imunoglobulíny [d12.776.124.486.485] + protilátky [d12.776.124.486.485.114] + protilátky monoklonálne [d12.776.124.486.485.114.224] + protilátky monoklonálne humanizované [d12.776.124.486.485.114.224.060] + abciximab [d12.776.124.486.485.114.224.060.125] adalimumab `[d12.776.124.486.485.114.224.060.250]` alemtuzumab [d12.776.124.486.485.114.224.060.313] baziliximab [d12.776.124.486.485.114.224.060.344] bevacizumab [d12.776.124.486.485.114.224.060.375] brentuximab vedotin [d12.776.124.486.485.114.224.060.438] certolizumab pegol [d12.776.124.486.485.114.224.060.500] cetuximab [d12.776.124.486.485.114.224.060.750] daklizumab [d12.776.124.486.485.114.224.060.766] denosumab [d12.776.124.486.485.114.224.060.782] gemtuzumab [d12.776.124.486.485.114.224.060.790] inotuzumab ozogamicín [d12.776.124.486.485.114.224.060.794] ipilimumab [d12.776.124.486.485.114.224.060.798] natalizumab [d12.776.124.486.485.114.224.060.813] nivolumab [d12.776.124.486.485.114.224.060.829] omalizumab [d12.776.124.486.485.114.224.060.844] palivizumab [d12.776.124.486.485.114.224.060.860] panitumumab [d12.776.124.486.485.114.224.060.864] ramucirumab [d12.776.124.486.485.114.224.060.866] ranibizumab [d12.776.124.486.485.114.224.060.868] trastuzumab [d12.776.124.486.485.114.224.060.875] + ustekinumab [d12.776.124.486.485.114.224.060.937]
	`[d12.776.124.790.651.114.224.060.250]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + globulíny sérové [d12.776.124.790] + imunoglobulíny [d12.776.124.790.651] + protilátky [d12.776.124.790.651.114] + protilátky monoklonálne [d12.776.124.790.651.114.224] + protilátky monoklonálne humanizované [d12.776.124.790.651.114.224.060] + abciximab [d12.776.124.790.651.114.224.060.125] adalimumab `[d12.776.124.790.651.114.224.060.250]` alemtuzumab [d12.776.124.790.651.114.224.060.375] baziliximab [d12.776.124.790.651.114.224.060.407] bevacizumab [d12.776.124.790.651.114.224.060.438] brentuximab vedotin [d12.776.124.790.651.114.224.060.469] certolizumab pegol [d12.776.124.790.651.114.224.060.500] cetuximab [d12.776.124.790.651.114.224.060.750] daklizumab [d12.776.124.790.651.114.224.060.766] denosumab [d12.776.124.790.651.114.224.060.782] gemtuzumab [d12.776.124.790.651.114.224.060.790] inotuzumab ozogamicín [d12.776.124.790.651.114.224.060.794] ipilimumab [d12.776.124.790.651.114.224.060.798] natalizumab [d12.776.124.790.651.114.224.060.813] nivolumab [d12.776.124.790.651.114.224.060.829] omalizumab [d12.776.124.790.651.114.224.060.844] palivizumab [d12.776.124.790.651.114.224.060.860] panitumumab [d12.776.124.790.651.114.224.060.864] ramucirumab [d12.776.124.790.651.114.224.060.866] ranibizumab [d12.776.124.790.651.114.224.060.868] trastuzumab [d12.776.124.790.651.114.224.060.875] + ustekinumab [d12.776.124.790.651.114.224.060.937]
	`[d12.776.377.715.548.114.224.200.250]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + globulíny [d12.776.377] + globulíny sérové [d12.776.377.715] + imunoglobulíny [d12.776.377.715.548] + protilátky [d12.776.377.715.548.114] + protilátky monoklonálne [d12.776.377.715.548.114.224] + protilátky monoklonálne humanizované [d12.776.377.715.548.114.224.200] + abciximab [d12.776.377.715.548.114.224.200.125] adalimumab `[d12.776.377.715.548.114.224.200.250]` alemtuzumab [d12.776.377.715.548.114.224.200.375] baziliximab [d12.776.377.715.548.114.224.200.407] bevacizumab [d12.776.377.715.548.114.224.200.438] brentuximab vedotin [d12.776.377.715.548.114.224.200.469] certolizumab pegol [d12.776.377.715.548.114.224.200.500] cetuximab [d12.776.377.715.548.114.224.200.750] daklizumab [d12.776.377.715.548.114.224.200.766] denosumab [d12.776.377.715.548.114.224.200.782] gemtuzumab [d12.776.377.715.548.114.224.200.790] inotuzumab ozogamicín [d12.776.377.715.548.114.224.200.794] ipilimumab [d12.776.377.715.548.114.224.200.798] natalizumab [d12.776.377.715.548.114.224.200.813] nivolumab [d12.776.377.715.548.114.224.200.829] omalizumab [d12.776.377.715.548.114.224.200.844] palivizumab [d12.776.377.715.548.114.224.200.860] panitumumab [d12.776.377.715.548.114.224.200.864] ramucirumab [d12.776.377.715.548.114.224.200.866] ranibizumab [d12.776.377.715.548.114.224.200.868] trastuzumab [d12.776.377.715.548.114.224.200.875] + ustekinumab [d12.776.377.715.548.114.224.200.937]

Stromová štruktúra MeSH - adalimumab

predmetové heslo

3.infliximab

	Stromová štruktúra MeSH - infliximab `[d12.776.124.486.485.114.224.608]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + imunoproteíny [d12.776.124.486] + imunoglobulíny [d12.776.124.486.485] + protilátky [d12.776.124.486.485.114] + protilátky monoklonálne [d12.776.124.486.485.114.224] + protilátky monoklonálne humanizované [d12.776.124.486.485.114.224.060] + protilátky monoklonálne myšie [d12.776.124.486.485.114.224.075] + terapeutiká protilátkové kombinované [d12.776.124.486.485.114.224.342] infliximab `[d12.776.124.486.485.114.224.608]` protilátky jednoreťazcové [d12.776.124.486.485.114.224.785]
	`[d12.776.124.790.651.114.224.537]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + proteíny krvné [d12.776.124] + globulíny sérové [d12.776.124.790] + imunoglobulíny [d12.776.124.790.651] + protilátky [d12.776.124.790.651.114] + protilátky monoklonálne [d12.776.124.790.651.114.224] + protilátky monoklonálne humanizované [d12.776.124.790.651.114.224.060] + protilátky monoklonálne myšie [d12.776.124.790.651.114.224.075] + terapeutiká protilátkové kombinované [d12.776.124.790.651.114.224.306] infliximab `[d12.776.124.790.651.114.224.537]`
	`[d12.776.377.715.548.114.224.642]` aminokyseliny, peptidy a proteíny [d12] + proteíny [d12.776] + globulíny [d12.776.377] + globulíny sérové [d12.776.377.715] + imunoglobulíny [d12.776.377.715.548] + protilátky [d12.776.377.715.548.114] + protilátky monoklonálne [d12.776.377.715.548.114.224] + protilátky monoklonálne humanizované [d12.776.377.715.548.114.224.200] + protilátky monoklonálne myšie [d12.776.377.715.548.114.224.284] + terapeutiká protilátkové kombinované [d12.776.377.715.548.114.224.463] infliximab `[d12.776.377.715.548.114.224.642]`

Stromová štruktúra MeSH - infliximab

`[d12.776.124.486.485.114.224.608]`

aminokyseliny, peptidy a proteíny [d12] +
- proteíny [d12.776] +
  - proteíny krvné [d12.776.124] +
    - imunoproteíny [d12.776.124.486] +
      - imunoglobulíny [d12.776.124.486.485] +
        protilátky [d12.776.124.486.485.114] +
        protilátky monoklonálne [d12.776.124.486.485.114.224] +
        protilátky monoklonálne humanizované [d12.776.124.486.485.114.224.060] +
        protilátky monoklonálne myšie [d12.776.124.486.485.114.224.075] +
        terapeutiká protilátkové kombinované [d12.776.124.486.485.114.224.342]
        infliximab [d12.776.124.486.485.114.224.608]
        protilátky jednoreťazcové [d12.776.124.486.485.114.224.785]

`[d12.776.124.790.651.114.224.537]`

aminokyseliny, peptidy a proteíny [d12] +
- proteíny [d12.776] +
  - proteíny krvné [d12.776.124] +
    - globulíny sérové [d12.776.124.790] +
      - imunoglobulíny [d12.776.124.790.651] +
        protilátky [d12.776.124.790.651.114] +
        protilátky monoklonálne [d12.776.124.790.651.114.224] +
        protilátky monoklonálne humanizované [d12.776.124.790.651.114.224.060] +
        protilátky monoklonálne myšie [d12.776.124.790.651.114.224.075] +
        terapeutiká protilátkové kombinované [d12.776.124.790.651.114.224.306]
        infliximab [d12.776.124.790.651.114.224.537]

`[d12.776.377.715.548.114.224.642]`

aminokyseliny, peptidy a proteíny [d12] +
- proteíny [d12.776] +
  - globulíny [d12.776.377] +
    - globulíny sérové [d12.776.377.715] +
      - imunoglobulíny [d12.776.377.715.548] +
        protilátky [d12.776.377.715.548.114] +
        protilátky monoklonálne [d12.776.377.715.548.114.224] +
        protilátky monoklonálne humanizované [d12.776.377.715.548.114.224.200] +
        protilátky monoklonálne myšie [d12.776.377.715.548.114.224.284] +
        terapeutiká protilátkové kombinované [d12.776.377.715.548.114.224.463]
        infliximab [d12.776.377.715.548.114.224.642]

predmetové heslo

4.nekróza

	Stromová štruktúra MeSH - nekróza `[c23.550.717]` stavy patologické, príznaky a symptómy [c23] + procesy patologické [c23.550] + akantolýza [c23.550.035] arytmie srdcové [c23.550.073] + ascites [c23.550.081] remodelácia predsiení [c23.550.113] azotémia [c23.550.145] kardiotoxicita [c23.550.161] kanalopatie [c23.550.177] aberácie chromozómové [c23.550.210] + smrť [c23.550.260] + dehydratácia [c23.550.274] funkcia štepu, oneskorená [c23.550.277] choroba [c23.550.288] + atribúty choroby [c23.550.291] + dysbióza [c23.550.308] emfyzém [c23.550.325] + extravazácia diagnostických a terapeutických látok [c23.550.340] + impingement femoracetabulárny [c23.550.347] fibróza [c23.550.355] + krehkosť [c23.550.359] nestabilita genómová [c23.550.362] + glióza [c23.550.369] granulóm [c23.550.382] + granulomatóza orofaciálna [c23.550.384] poruchy rastu [c23.550.393] + hemolýza [c23.550.403] hemorágia [c23.550.414] + hyperamonémia [c23.550.421] hyperamylazémia [c23.550.425] hyperbilirubinémia [c23.550.429] + hyperplázia [c23.550.444] hyperurikémia [c23.550.449] hypovolémia [c23.550.455] zápal [c23.550.470] + komplikácie peroperačné [c23.550.505] + ischémia [c23.550.513] + leukoaraióza [c23.550.522] leukocytóza [c23.550.526] litiáza [c23.550.537] účinky nežiaduce dlhodobé [c23.550.543] malakoplakia [c23.550.548] poruchy menštruačné [c23.550.568] + metaplázia [c23.550.589] + slabosť svalová [c23.550.695] + myotoxicita [c23.550.706] nekróza `[c23.550.717]` nekróza zubnej drene [c23.550.717.182] degradácia DNA, nekrotická [c23.550.717.273] nekróza tuková [c23.550.717.365] gangréna [c23.550.717.427] infarkt [c23.550.717.489] + osteonekróza [c23.550.717.732] + neointima [c23.550.722] procesy nádorové [c23.550.727] + degenerácia nervov [c23.550.737] + ochronóza [c23.550.744] osifikácia heterotopická [c23.550.751] + ototoxicita [c23.550.753] poruchy pigmentácie [c23.550.755] polydipsia [c23.550.759] + komplikácie pooperačné [c23.550.767] + agregácia patologických proteínov [c23.550.770] aspirácia do dýchacích ciest [c23.550.773] + retropneumoperitoneum [c23.550.794] skleróza [c23.550.823] šok [c23.550.835] + teratogenéza [c23.550.863] neuropatia toxická optická [c23.550.877] vred [c23.550.891] remodelácia ciev [c23.550.918] nedostatok princípu jang [c23.550.945] nedostatok princípu jin [c23.550.972]

Stromová štruktúra MeSH - nekróza

`[c23.550.717]`

stavy patologické, príznaky a symptómy [c23] +
- procesy patologické [c23.550] +

predmetové heslo

5.syndróm lýzy nádoru

	Stromová štruktúra MeSH - syndróm lýzy nádoru `[c15.604.515.880]` choroby krvné a lymfatické [c15] + choroby lymfatické [c15.604] + poruchy lymfoproliferatívne [c15.604.515] + agamaglobulinémia [c15.604.515.032] syndróm autoimunitný lymfoproliferatívny [c15.604.515.138] Castlemanova choroba [c15.604.515.245] granulóm [c15.604.515.292] + choroba z ťažkých reťazcov [c15.604.515.435] + lymfadenopatia imunoblastická [c15.604.515.509] mononukleóza infekčná [c15.604.515.516] leukémia vlasatobunková [c15.604.515.553] leukémia lymfoidná [c15.604.515.560] + lymfangiomyóm [c15.604.515.562] + lymfóm [c15.604.515.569] + Marekova choroba [c15.604.515.700] sarkoidóza [c15.604.515.827] + Sézaryho syndróm [c15.604.515.841] syndróm lýzy nádoru `[c15.604.515.880]` Waldenströmova makroglobulinémia [c15.604.515.925]
	`[c20.683.515.950]` choroby imunitného systému [c20] + poruchy imunoproliferačné [c20.683] + poruchy lymfoproliferatívne [c20.683.515] + syndróm autoimunitný lymfoproliferatívny [c20.683.515.124] Castlemanova choroba [c20.683.515.250] lymfadenopatia imunoblastická [c20.683.515.501] amyloidóza ľahkých reťazcov [c20.683.515.507] choroba tenkého čreva, imunoproliferačná [c20.683.515.512] mononukleóza infekčná [c20.683.515.515] leukémia vlasatobunková [c20.683.515.517] leukémia lymfoidná [c20.683.515.528] + lymfangiomyóm [c20.683.515.710] + lymfóm [c20.683.515.761] + syndróm aktivácie makrofágov [c20.683.515.800] Marekova choroba [c20.683.515.840] myelóm mnohopočetný [c20.683.515.845] + plazmocytóm [c20.683.515.880] Sézaryho syndróm [c20.683.515.920] syndróm lýzy nádoru `[c20.683.515.950]`

Stromová štruktúra MeSH - syndróm lýzy nádoru

`[c15.604.515.880]`

choroby krvné a lymfatické [c15] +
- choroby lymfatické [c15.604] +
  - poruchy lymfoproliferatívne [c15.604.515] +

`[c20.683.515.950]`

choroby imunitného systému [c20] +
- poruchy imunoproliferačné [c20.683] +
  - poruchy lymfoproliferatívne [c20.683.515] +

predmetové heslo

1.certolizumab pegol

Stromová štruktúra MeSH - certolizumab pegol

`[d05.750.741.125]`

`[d12.644.541.500.650.250]`

`[d12.776.124.486.485.114.224.060.500]`

`[d12.776.124.486.485.680.650.250]`

`[d12.776.124.790.651.114.224.060.500]`

`[d12.776.124.790.651.680.650.250]`

`[d12.776.377.715.548.114.224.200.500]`

`[d12.776.377.715.548.680.650.250]`

2.adalimumab

Stromová štruktúra MeSH - adalimumab

`[d12.776.124.486.485.114.224.060.250]`

`[d12.776.124.790.651.114.224.060.250]`

`[d12.776.377.715.548.114.224.200.250]`

3.infliximab

Stromová štruktúra MeSH - infliximab

`[d12.776.124.486.485.114.224.608]`

`[d12.776.124.790.651.114.224.537]`

`[d12.776.377.715.548.114.224.642]`

4.nekróza

Stromová štruktúra MeSH - nekróza

`[c23.550.717]`

5.syndróm lýzy nádoru

Stromová štruktúra MeSH - syndróm lýzy nádoru

`[c15.604.515.880]`

`[c20.683.515.950]`